细菌凝血菌独特的IS2改善了健康成年人的便特征不经常排便:一个随机,双盲,安慰剂对照的试验
A LeMoire1, R Replogle2, L Shinn2
1419393Nutrasource Pharmaceutical and Nutraceutical Services, Inc. Guelph, ON, Canada.
Beneficial microbes
|June 2, 2025
概括
细菌凝血素独特IS2补充剂显著增加了肠道运动频率和改善了硬便的成年人的便一致性. 这种益生菌在4周的时间内证明了安全性和耐受性.
科学领域:
- 胃肠病学 胃肠病学
- 微生物学 微生物学
- 临床营养学 临床营养学
背景情况:
- 消化系统健康问题,包括不规则的肠道排便和胃肠道症状,很普遍,并且与疾病风险增加有关.
- 细菌凝血菌是一种益生菌,对肠道健康有潜在的益处.
研究的目的:
- 研究Bacillus coagulans Unique IS2在改善便特征和减少胃肠道症状方面的疗效.
- 评估B.coagulans Unique IS2对肠道排便频率,便一致性和生活质量的影响.
主要方法:
- 一项随机,双盲,安慰剂控制的研究,涉及144名健康成年人,具有特定的肠道排便标准.
- 参与者接受了B.coagulans Unique IS2 (每天20亿CFU) 或安慰剂4周.
- 结果包括排便频率的变化,便的一致性 (布里斯托尔便形状量表),胃肠道症状和肠道微生物群.
主要成果:
- B.凝固剂 独特的IS2显著增加了肠道排便频率 (P = 0.037).
- 在B.coagulans Unique IS2组,每周便的一致性显著改善 (P < 0.05),硬便发生率显著改善 (P = 0.001).
- 没有观察到对胃肠道症状,生活质量,肠道微生物群或完全自发排便比例的显著影响.
结论:
- B. coagulans Unique IS2是一种安全且耐受良好的益生菌.
- 它显示出作为改善便特征的战略的承诺,特别是对于经历硬便和便质量差的人来说.
相关概念视频
Drugs for Treatment of Constipation-Predominant IBS
732
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
732
Drugs for Treatment of Diarrhea-Predominant IBS
636
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
636
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
736
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
736
Irritable Bowel Syndrome I: Introduction
929
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
929
Chronic Bowel Disorders: Introduction
748
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
748
Drugs Affecting GI Tract Motility: Bulk-Forming and Stimulant Laxatives
531
Laxatives enhance bowel movements and alleviate constipation. They augment the stool's bulk, stimulate intestinal muscle contractions, draw water into the intestines, or soften the stool. There are five key types of laxatives: bulk laxatives, stimulant laxatives, osmotic laxatives, stool softeners, and lubricant laxatives.
Bulk-forming laxatives, such as psyllium, methylcellulose, and polycarbophil, absorb water in the intestine, increasing stool bulk and promoting bowel movement. This...
Bulk-forming laxatives, such as psyllium, methylcellulose, and polycarbophil, absorb water in the intestine, increasing stool bulk and promoting bowel movement. This...
531


